Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that members of its executive leadership team will present and host investor meetings at several upcoming conferences. **Details on the ...

The company's recent appearance at the Frankfurt Equity Forum left many strategic questions unanswered, highlighting the significant challenges Evotec faces in its future strategic positioning. Fresh ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report), with a price ...

Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. Shares up.

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $49 which represents a slight increase of $3.30 or 7.22% from the prior close of $45.7. The stock opened at ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was enjoyable and invigorating, ...

Halozyme Therapeutics stock is trading -21.53% below its average target price of $62.44 after marking a 7.2% during today's ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...